Iron Overload clinical trials

The registry lists 164 studies for Iron Overload across more than 10 countries. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-16.

Studies

Recruiting first, then most recently updated. Showing 50 of 164 — search for more.

• Fully Automated High-Throughput Quantitative MRI of the LiverRecruitingNCT052944711 country
• Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary HemochromatosisRecruitingNCT07332091Phase 218 countries
• Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingNCT07023666Phase 21 country
• Neurodegenerative Diseases Progression Markers (MARKERS-NDD)RecruitingNCT065967461 country
• Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.RecruitingNCT070281121 country
• Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.Not yet recruitingNCT07352878
• Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron AbsorptionRecruitingNCT061466081 country
• "Iron Overload and Endocrinological Diseases"RecruitingNCT061370791 country
• Thalassemic Iron Overload Cardiomyopathy is Ameliorated by Taurine SupplementationRecruitingNCT04291352Not applicable1 country
• Apotransferrin in AtransferrinemiaActive, not recruitingNCT01797055Phase 23 countries
• Treatment of HemochromatosisActive, not recruitingNCT00007150Phase 21 country
• Evaluate the Efficacy and Safety of Irochel for the Management of Iron Overload in Thalassemia Patients in Comparison With DeferoxamineCompletedNCT07782931Phase 31 country
• Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary StudyCompletedNCT015563601 country
• Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNCT02880033Not applicable1 country
• Iron Accumulation in Erythrocytes in PatientsCompletedNCT074865311 country
• Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating TherapyCompletedNCT041716351 country
• Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsCompletedNCT02164253Phase 21 country
• Elastography vs Iron Regulators in the Diagnosis of Hepatic Fibrosis- Iron Overload in Children With Beta- ThalassemiaCompletedNCT071539261 country
• Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron ContentCompletedNCT020255431 country
• Ethnic Differences in Iron Absorption (FeGenes)Active, not recruitingNCT041985451 country
• Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy AdultsCompletedNCT06726863Phase 11 country
• Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCTCompletedNCT044232371 country
• Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded PatientsCompletedNCT05355766Phase 21 country
• Inhibitory Effect of a Polyphenol Supplement on Dietary Iron Absorption in Adults with ThalassemiaCompletedNCT05326503Not applicable1 country
• Safety of SP-420 in the Treatment of Transfusional Iron OverloadTerminatedNCT04741542Phase 11 country
• Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron OverloadCompletedNCT02435212Phase 217 countries
• Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadCompletedNCT06468423Not applicable1 country
• Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational MaterialsCompletedNCT062152871 country
• MRI QSM Imaging for Iron OverloadCompletedNCT046317181 country
• Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnNCT01892644Phase 21 country
• Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedNCT03591575Phase 42 countries
• Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02443545Phase 45 countries
• Long-term Clinical Study of CN128 in Thalassemia PatientsCompletedNCT04614779Phase 21 country
• Changes in Pituitary Iron and Volume With DeferasiroxCompletedNCT013766221 country
• NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia MajorStatus unknownNCT05777733Phase 1
• Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance ImagingCompletedNCT00401336Not applicable2 countries
• Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic LiversiderosisCompletedNCT01045525Phase 31 country
• Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)Status unknownNCT00907283Phase 21 country
• Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDSTerminatedNCT03920657Phase 21 country
• Study to Assess Iron Chelation Therapy in Patients With Chronic Iron OverloadCompletedNCT054404871 country
• Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl HydrazoneCompletedNCT00000588Phase 2
• A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary HemochromatosisCompletedNCT03395704Phase 24 countries
• The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin LevelsTerminatedNCT037779041 country
• Evaluation of Hepatic Affection in Hemodialysis Patients With Iron Overload in Assiut University HospitalCompletedNCT050285951 country
• Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00110266Phase 22 countries
• Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron OverloadCompletedNCT00901199Phase 21 country
• Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02041299Phase 48 countries
• A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta ThalassemiaTerminatedNCT03381833Phase 28 countries
• Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCompletedNCT01254227Phase 28 countries
• Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron OverloadCompletedNCT03802916Phase 24 countries